Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
m48etHTMfb0aUVUT
